MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, July 3, 2009


Information provided by Carmen B., in Miami

American Heart Association reports percentage meeting cholesterol standards has doubled in decade; study from Netherlands finds statins can protect nerve cells against damage known to occur in Alzheimer's


June 22, 2009 – The news for statins today was great. The American Heart Association credits statins as a significant reason that the percentage of people lowering their elevated “bad” cholesterol to within the recommended range has almost doubled in the last decade. And, from The Netherlands comes a study showing statins can protect us from Alzheimer’s disease.

The good newsabout the dramatic reduction in “bad” cholesterol comes from a multi-national survey reported today in Circulation: Journal of the American Heart Association.

In the Lipid Treatment Assessment Project (L-TAP) 2 — a survey of nearly 10,000 patients (average age 62) from nine countries undergoing cholesterol-lowering and management efforts — researchers found that:

» Read More


Clinical Trial Update On Therapeutic Effects Of Combined Treatment With Ribavirin And Tiazofurin

2 - Jul- 2009
Hard To Treat Diseases (HTDS) Chief Scientist with its Slavica BioChem subsidiary, Dr. Sanja Pekovic provided updates on recent clinical trials with animal subjects in regards to the use of Ribavirin And Tiazofurin for the potential treatment of Multiple Sclerosis (MS).

Dr. Pekovic reported; "It is now well accepted that axonal injury begins at an early stage in MS, and likely accounts for clinical progression seen later in the disease course, suggesting that early, aggressive treatment is critical in order to suppress long-term disability progression. Researchers from IBISS group (a related research group) tested the effect of combined treatment with ribavirin (R) and tiazofurin (T) administrated during the effecter phase of disease.

Read More


Keep Current with MS information by registering at our website - After registering you will begin receiving the weekly MS e-Newsletter called "Stu's Views and MS Related News".This weekly publication is being received in (48) countries.If not yet receiving this, join now, to not miss another issue. - thank you

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed No Clinically Relevant Benefit For Patients

July 2, 2009
UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted.

CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis.

Read More

MS related : Sex and Intimacy - Learn Online

MS Learn Online Presents
Today's new Feature Presentation

Sex and Intimacy
featuring Rosalind Kalb, PhD
focuses on:
  • Sexual dysfunction
  • Management strategies
  • Improving intimacy
Click here to view the webcast, or
copy into your browser:
If you have a pop-up blocker, you will need to disable it prior to participating in a MS Learn Online webcast.


Keep Current with MS information by registering at our website - After registering you will begin receiving the weekly MS e-Newsletter called "Stu's Views and MS Related News". This weekly publication is being received in (48) countries.If not yet receiving this, join now, to not miss another issue. - thank you

Low Dose Naltrexone info for those with MS

Information provided by Sammy Jo in Washington...

Stanford released positive results from their fibromyalgia trial in April 09 and are starting phase 2. They are alos initiating LDN research for Gulf War Syndrome.
Stanford also received patient funding for this research, similar to the LD-MS trial at UCSF in 2006 which was funded by patients. There is also news this week from Penn State that an MS patient who got great results from LDN donated $50,000 to their MS research, and a Parkinson's patient donated $75,000 to their LDN for PD research as well.

Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You

The National MS Society Needs YOUR help - Please complete this survey

Dear All affected by MS
(Patients, Caregivers, Friends, Colleagues, and Health Care Providers),

I hope you’re well and looking forward to a wonderful 4th of July weekend.

The MS Society asked me if I would consider posting the link and information found below. Inviting all of you to participate, would be a great help to their outreach effort.

The National MS Society is in the process of gathering information that will help them better understand what needs to "happen" and "change", to help people affected by MS keep moving their lives forward.

This information will help guide the Society’s direction for the next five years. The survey is completely confidential and requires just a few minutes to complete.

Thanks in advance, and have a wonderful 4th of July weekend.

Remember that the National MS Society is the Largest MS Organization and it would be to your advantage for they to know what they are asking from each of you. They asked Me (and MS Views and News/Stu's Views & M.S. News) to help distribute their survey --- Let's Show them what they seek to know. Please pass this message onward to others whom you know ARE affected by MS.

Register with "MS Views and News" {a 501(c)3 - Not for Profit}. Using state-of-the-art technology to bring to those affected by MS, knowledge and information concerning Multiple Sclerosis. In registering, you will receive our weekly published MS related e-Newsletter. Visit to register. - thank you


Thursday, July 2, 2009

In Australia - The TGA backs Tysabri

Pharmacy News

Mark Gertskis

Drug regulators are standing by a multiple sclerosis drug that has been associated with a potentially-deadly brain infection.

Pharmacy News revealed that Tysabri (natalizumab) has been linked to 10 cases of progressive multifocal leukoencephalopathy (PML) across the world since 2006, with the latest case occurring as recently as 23 June.

The Therapeutic Goods Administration (TGA) confirmed that no cases of PML in Tysabri patients had been reported in Australia to date and said it would monitor the situation.

"The benefits of this drug in a serious and disabling medical condition are considered significant," a TGA statement said.

The drug's product and consumer information already carried a black box warning about its association with the condition, the TGA said.

Tysabri was temporarily taken off the US market in 2005 due initial concerns of a link to PML but registered in Australia in November, 2006.

The drug's manufacturer, Biogen Idec, said it was not considering taking it off the market again.

"Tysabri's benefits clearly outweigh its risks," Biogen Idec spokesman Jose Juves said.

"To date, the rate of PML in Tysabri-treated patients is lower than originally seen in the clinical trials. Nine of the 10 patients diagnosed with PML since 2006 are alive, telling us that PML may not be uniformly fatal in Tysabri-treated patients.

"Overall, PML is occurring less frequently and may be less fatal than originally thought when Tysabri was approved."



Study Shows Link Between Gulf War Service and MS

By MICHAEL KUHNE Daily American Correspondent

JOHNSTOWN. Pa. — Local veterans and members of the National Multiple Sclerosis Society gathered in the Holiday Inn along Market Street Wednesday to recognize U.S. Rep. John Murtha for securing funds for medical research.

Approximately $5 million has been allocated to the society through the U.S. Department of Defense. Murtha secured the funding through the Congressionally Directed Medical Research Program.

“We’re here to thank Congressman Murtha and to talk about an important program in achieving funding for medical research,” said David Chatel, executive vice president of advocacy for the organization.

The funding has been the result of efforts by society members and veterans seeking more research to answer questions about the disease, board Chairman Robert Bernstein said.


Wednesday, July 1, 2009

Update on Tysabri and PML

Source: National MS Society

Jun 30, 2009

According to Biogen Idec, a tenth confirmed case of progressive multifocal leukoencephalopathy (PML, a viral infection of the brain that usually leads to death or severe disability) has occurred among people who have used Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) after it became available for prescription in July 2006. The case, reported by the company on June 26, 2009, occurred in a person in Europe who had been taking Tysabri for 30 months. The reported duration of use among these ten people has ranged from about 12 to 35 months.

As of the end of March 2009, 40,000 people worldwide were being prescribed Tysabri. Although the absolute risk for PML in patients treated with Tysabri cannot be precisely determined, the frequency to date remains less than the one-in-one thousand risk that was estimated at the time of Tysabri’s re-approval in 2006.

It appears that when PML is detected and treated early, it generally improves outcomes. It is important that individuals taking this drug and their doctors be vigilant in monitoring for any occurrence of new, unusual symptoms that might indicate PML.
Typical symptoms associated with PML progress over days to weeks, and can include:
• clumsiness and progressive weakness on one side of the body,
• disturbances of vision, and
• changes in thinking, memory, and orientation leading to confusion and personality changes.

If individuals taking Tysabri experience new, unusual symptoms, they should contact their prescribing physician immediately. Physicians who need guidelines on the protocol to follow when they have a patient on Tysabri who experiences unusual symptoms should contact Biogen Idec.

There is no specific therapy to treat PML, but the best hope is to reconstitute a person’s immune responses. Based on small-scale studies supported by Biogen Idec, plasma exchange, a blood-cleansing treatment, has been used to clear the bloodstream of Tysabri. There is insufficient evidence to determine whether plasma exchange can reduce PML symptoms.

For a company-released update on Tysabri use and postmarketing cases of PML, go to its Website.

Tysabri is a registered trademark of Biogen Idec and Elan.


Biogen gains rights outside U.S. to Acorda MS drug

* Biogen gains overseas rights to Fampridine-SR

* Biogen makes up-front payment of $110 mln

* Acorda shares fall 12 pct; Biogen up 2.55 pct (Adds analyst comment and byline; updates share prices)

CLICK to read this article from Reuters


Relationship between Psychosocial Factors and Onset of Multiple Sclerosis

Information provided by Karen in Tamarac, Fl.

Click to read: Relationship between Psychosocial Factors and Onset of Multiple Sclerosis

Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You

MS study offers theory for why repair of brain's wiring fails

Eureka Alert
July 1, 2009

Scientists have uncovered new evidence suggesting that damage to nerve cells in people with multiple sclerosis accumulates because the body's natural mechanism for repair of the nerve coating called "myelin" stalls out.

The study, published today, July 1, 2009, in the print edition of "Genes & Development," was conducted by scientists at the University of California, San Francisco and University of Cambridge. The research was led by co-senior investigator David Rowitch, MD, PhD, a Howard Hughes Medical Institute investigator at UCSF.

The investigation, conducted in mice and in human tissue, showed that repair of nerve fibers is hampered by biochemical signals that inhibit the development of cells known as oligodendrocytes, which function as repair workers in the brain.

Oligodendrocytes form a protective sheath, known as myelin, that insulates the fibrous cables, or axons, radiating from nerve cells. In multiple sclerosis, the immune system's T cells and B cells attack oligodendrocytes, ultimately damaging the myelin sheath to the point that the electrical signals transmitted by the axons beneath it are disrupted.

Remarkably, the brain generally is able to recruit fresh, immature oligodendrocytes to the myelin sheath to repair the damage, for a time. This explains why, in the most common form of the disease, known as relapsing remitting MS, the symptoms -- which range from tingling and numbness in the limbs to loss of vision and paralysis -- disappear or are greatly reduced, for some times months or years at a time.

Click here, to continue to read from the 6th paragraph


Fampridine-SR update from Acorda Therapeutics

Acorda Therapeutics Inc has added a news release to its Investor Relations website.

Title: Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.

Date: 7/1/2009 6:00:00 AM

If not yet registered to receive the "Stu's Views and MS Related News", weekly Multiple Sclerosis e-newsletter, then please Click Here to register.


Wheelchair Kamikaze: In Search of Audrey Hepburn

Video performed and narrated by Marc Steckler

At the request of a friend, The Wheelchair Kamikaze embarks on a quest to find a statue dedicated to Audrey Hepburn, located on the east side of Manhattan. The trip takes us through Central Park an...

Click here to review. Video is found halfway down the webpage that opens.

THIS can also be viewed towards the lower right of this page.
And for those that only see half an image of the videos found here, if you can view using Mozilla, you will be able to see everything.


MS Views and News is dedicated to the global collection and distribution of current information concerning Multiple Sclerosis

MS Views and News
MS Views and News is dedicated to the global collection
and distribution
of current information concerning Multiple Sclerosis.
In collaboration withother organizations, MS Views and News uses state-of-the-art communication channels to provide information for those affected by, or interested, in MS.
A Not For Profit 501(c) Organization

If not yet receiving our weekly MS related e-newsletter called:
Stu's Views and MS Related News
then please click here to register


The Myelin Project Presents: Wayne Osteen Home Giveaway Raffle Registration

The purchase of a raffle ticket enters you into a raffle for a chance to win a Wayne Osteen Custom home and proceeds benefit The Myelin Project.

Home specs

  • 1775 square feet
  • 3 Bedrooms
  • 2 baths
  • 2 car garage
  • 3600 Springfield, Amarillo, Randall County, TX
  • House is under construction
  • New subdivision on a new street
  • Two blocks from City View School, Amarillo's newest elementary school

Giveaway details

  • Tickets are $50.00
  • Only 4500 tickets will be sold
  • Ground breaking is Wednesday, June 24, 2009
  • Giveaway date is Sunday, October 18, 2009 at the house.
  • Raffle tickets will be mailed to the address entered on the form below
  • The Myelin Project will draw 100 tickets and those 100 ticket holders are the finalists
  • The 100 finalists will participate in a reverse raffle to select the winning ticket and house winner
  • The October 18 giveaway will be held at the house
  • The last ticket drawn will be the house winner
  • Other prizes will be given away
  • Results will then will be posted on The Myelin Project web site's home page
If you need more information, please contact Candace Root, Executive Director, The Myelin Project (800)-869-3546 or

VISIT HERE to complete Your registration for this Raffle

Tuesday, June 30, 2009

Continuous disease-modifying treatment without interruptions provides better long-term outcomes in MS

People with MS who adhere to their treatment with interferon (IFN) beta-1a without interruption have lower relapse and progression rates than people who do not not, said researchers here at the 19th Meeting of the European Neurological Society.

To read more, as reported by the UK MS Trust: click here.

Source: UK MS Trust


The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)

summary: In MS the perception of symptoms and how they impact quality of life varies significantly from one person to another. The perceived response to treatment, including rehabilitation, may also differ. In this article the authors aimed to evaluate a newly developed set of tests (called PRIMUS) which takes into account MS symptoms in a holistic way, from the point of view of the person with MS. The authors concluded that scores obtained from PRIMUS are reliable and very useful in detecting how the disease impacts on the person with MS.

authors: Doward L, McKenna S, Meads D, Twiss J, Eckert B

source: Mult Scler. 2009 Jun 25

weblink: click here


Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study

summary: There are very few studies of cognitive dysfunction in people with primary progressive MS (PPMS). In this study the authors compared a group of people with primary progressive MS with a group of secondary progressive MS and a group of healthy volunteers. They found that (SPMS) people with MS scored lower than controls on some tests, such as those related to attention and information processing, verbal fluency and memory. However, people with PPMS and with SPMS performed tests similarly. Moreover, the authors found that people with a higher number of lesions performed worse than people with a lower lesion burden.

authors: Ukkonen M, Vahvelainen T, Hämäläinen P, Dastidar P, Elovaara I

source: Mult Scler. 2009 Jun 25

weblink: click here

Information source:

Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You

An MS Patients' Diary of his Stem Cell Therapy treatment

Written By: Preston Walker

After undergoing adult stem cell treatment in May 2008 for multiple sclerosis, I felt better than I had in several years. About 10 months after the treatment, I noticed my depression and fatigue symptoms had returned. I recognized this as the beginning symptoms of what I experienced in the late 90's that ultimately led to my diagnosis in December 2001. I wanted to catch the disease before it progressed any further. I had already done my research leading up to the eventual trip to Costa Rica. After the first treatment going as well as it did, I didn't have to do any more research. I made arrangements to hop back on a plane for more therapy through the Institute of Cellular Medicine (ICM) in San Jose, Costa Rica.

Staff at ICM was still as compassionate as I remember from my initial treatment. I can't imagine a better experience with staff at a clinic, anywhere.

I again stayed at the Apartotel Christina. ICM left my treatment schedule within my room. I discovered my treatment would consist of another mini-liposuction, two intravenous injections of stem cells taken from my fat tissue, two intrathecal injections and three sessions of physical therapy.
I went through my second intrathecal injection as well as my second IV injection of stem cells taken from my own fat.

A hint on the injections. The intrathecal (into the spinal cord) sounds very painful. The procedure has been compared to an epidural that most women allow during child birth. My wife told me she didn't feel it because well,,she was distracted!! It is not much different for the guys with the exception that we aren't giving birth!! I barely felt either injection.

When I underwent the mini-liposuction, they didn't take any fat from the same areas they did last year. Specifically, fat was taken from my inner thighs and lower back. Before the IV injection of those stem cells, Dr. Tomas told me staff at CIMA hospital was unable to get enough stem cells to only use mine so she coupled the injection with adult stem cells taken from donated umbilical cords.

Apparently the magic number for the injections is 50 million stem cells. The second mini-lipo was a little more painful than the first. I can summarize that experience and my outlook on the pain with this, if I must endure pain with hope of improving my quality of life - bring on the pain!!!
I compared the physical therapists at CIMA hospital to drill sergeants in United States Army boot camp that I experienced in 1987 where some very serious "learning" exercises were provided. That was long ago but they made a lasting impression on me.

My drill sergeant in 2009 is named Jennifer. The one thing you can say about the physical therapists at CIMA hospital is that they are consistently trained!! They are very compassionate but tough as nails. When my physical therapy sessions concluded, she concluded my session by giving me printed instructions on the exercises we had been doing. .

There is one change this time. Dr. Riordan and staff are keeping 20% of the stem cells for use should I ever need to come back. Dr. Riordan said he is doing that to keep us from undergoing another mini-liposuction.. I thank God for that man's intelligence!!

I haven't noticed much improvement yet from this second treatment. Possibly, my hopes should be more realistic. I didn't get here over night so the return to health will not happen quickly either.
Richard Humphries, whom I underwent stem cell injections with in 2008, had already returned for his second treatment. The difference between he and I is that a symptom of his MS involved the loss of hearing. His hearing improved dramatically after the first treatment. Richard returned because scientists there believed they discovered the stem cell responsible for inner ear hair growth. His return involved the hope that his hearing would be improved even more.

Richard experienced other improvements but they took several months to materialize and were more subtle. He has already been through this for the second time so, I wait patiently. I will keep you informed as I notice any improvements.

More updates to follow as time permits

PLEASE Leave your comments

Not yet receiving Stu's Views and MS Related News? Keep current with a weekly digest of MS information. Register with "MS Views and News" {a 501(c)3 - Not for Profit}. Using state-of-the-art technology to bring to those affected by MS, knowledge and information concerning Multiple Sclerosis. In registering, you will receive our weekly published MS related e-Newsletter. Visit to register. - thank you

Heat and MS: Okay, it's officially hot now...

Written By Julie Stachowiak, Ph.D., Guide to Multiple Sclerosis
Tuesday June 30, 2009

Okay, it's official. It's hot. It's humid. This means that for those of us with MS we have a choice - stay inside and be kinda mad and anxious about summer, or go outside and be REALLY mad and anxious about summer.

I'm bringing up these articles again to remind us that, even though it is that time of year, there are some things we can do to keep functioning the best we can. It is also to remind us that, if we feel a little slower, a little bit MSier, forget and drop things more, not to be too hard on ourselves. Get a glass of iced tea, get in the pool or inside and take it easy.

Read the full articles:


45 New Projects Launched To Propel MS Research

source: National MS Society

Jun 23, 2009

The National Multiple Sclerosis Society has just committed $15.8 million to support 45 new MS research projects as part of its $40 million international investment this year alone to spur momentum in cutting-edge MS research. This financial commitment is the latest in the Society’s relentless research effort to prevent, treat and cure MS.

To ensure the scientific merit of each research proposal selected, the National MS Society relies on expert advisory committees that include more than 70 world-class scientists who volunteer their time to carefully evaluate hundreds of proposals every year.

The new projects include a comprehensive genome-wide exploration of susceptibility genes – the next definitive step to map all genes that make people susceptible to MS; a clinical trial to test the impact of vitamin D and how it alters the immune system in people who have MS; and an investigation of changes in the brain that may lead to personality and behavior disorders in MS.

Download a pdf about these new research projects.


BioScrip Commences Patient Enrollment in Teva Neuroscience Therapy Optimization in Multiple Sclerosis (Tops MS) Research Study

© Business Wire 2009
2009-06-30 14:20:03 -

BioScrip, Inc. (Nasdaq: BIOS) announced today that Teva Neuroscience tapped BioScrip Specialty Pharmacy as one of several national research study participants in one of the most comprehensive MS research studies announced to date.

TOP MS is a new research study for MS patients. The study will collect information, through online surveys about the quality of life, symptoms, relapse, employment, usual level of activity participation and general health activity from individuals living with MS for a two-year period.

“We are very pleased that BioScrip was selected as a specialty pharmacy study participant”, said Rick Smith, president and COO of BioScrip Inc.

“Teva recognized our BioscripCare™ MS program’s ability to provide high-quality, comprehensive and personalized MS care on a national basis. At BioScrip, we believe that this study will reaffirm our ongoing commitment to BioscripCare drug therapy adherence programs for patients and physician support services to improve the quality of life for the MS patient.”

READ MORE by clicking here

An MS Patient's own writings: Emotional Piracy

Emotional Piracy

I was watching a movie. "Hilary and Jackie". A moment greatly acted out, showing what it feels, how it feels to lose the world. She is alone and listening to what she sounded like, when she was a cellist of the world. Her face distorted, by the tears cascading down her body that is wracked too hard by a mistake created by the hand of man, while climbing up the ladder to better and surpass what exists upon our only home called Earth. I see the anger and her fear, confusion and disbelief of something ugly whose middle name is death. Too early and uninvited, sometimes painful and mystifying, it's given name is Multiple Sclerosis.

A very ugly little toad, who hides beneath the stagnant pool, a genetic pool called industrialization. The other toad, his wife, goes by another ugly name, abandonment is how it is defined. She is alone inside her illness, as I keep inside my illness, whose name I consider a mortal sin. We are left behind by illness not by family, friends or people, but betrayed by a fluke of nature we created. Inoculations paved the road to confuse our bodies nature, to protect, to defend against the beast. I am no pariah, nor in-activated woman who feels and needs the same as you or you. But, when I see her in her chair, wracked by spasms and well earned fears, of the future of her life, too shortly lived. She had become ' the cello player', the instrument itself, one cannot see the dancer from the dance. Understand if you choose, what it is to really lose, the only life I'm fairly certain of. Don't sing to me of forever, and the Pearly Gates of Heaven, I am here. I am alive. I am today.

Theresa Dould Cummings 09/14/08
*Jacqueline Du Prey's rendition of Elgar's Cello Concerto must be experienced. 'I am Elgar. I am this Concerto.'

To contact Theresa - write to: OR, leave a comment here. - thank you

Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You

“One teaspoon to be taken each morning with breakfast for one month.”

(as appeared in Hadassah Magazine, June/July 2009, Vol. 90 No. 8 )

Hadassah doctors, working with Harvard Medical School, are researching a groundbreaking liquid therapy to target and prevent autoimmune diseases.

Sometime in the next decade, there may be a prescription that reads “One teaspoon to be taken each morning with breakfast for one month.”

Thirty days later, the patients who follow these directions and swallow the liquid daily will find themselves free of their diabetes, lupus, multiple sclerosis, rheumatoid arthritis, Crohn’s disease, ulcerative colitis or whichever of the more than 80 other distinct and crippling auto-immune illnesses dispatched them to their doctor.


Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You

Monday, June 29, 2009

Cladribine Is Safe Overall in Patients With Multiple Sclerosis: Presented at ENS

By Judith Moser, MD

MILAN, Italy -- June 24, 2009 -- According to a safety analysis of a study presented here at the 19th Meeting of the European Neurological Society (ENS), the incidence of treatment-emergent adverse events in the trial was comparable between 2 doses of cladribine and placebo in patients with multiple sclerosis (MS), with exceptions related to the mechanism of action of cladribine.

In the 96-week phase 3, randomised, double-blind, placebo-controlled Cladribine Tablets Treating MS Orally (CLARITY) trial, cladribine tablets demonstrated significant efficacy in the treatment of patients with relapsing-remitting MS.



Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial

25 June 2009

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis (RRMS). BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex®.

The BRAVO study completed patient enrollment in June, recruiting more than 1,200 patients at 156 sites in the United States, Europe, Israel and South Africa.

“Teva and Active Biotech are encouraged by the potential of laquinimod to address patients' unmet need for an oral immunomodulating MS therapy that provides efficacy while maintaining safety” said Moshe Manor, Teva’s Group Vice President, Global Branded Products. “We look forward to continuing our clinical Phase III program of laquinimod, and hope it will offer enhanced quality of health for RRMS patients”.

ALLEGRO, the first global Phase III trial of laquinimod, completed enrollment in November 2008, after recruiting more than 1,000 patients at 152 sites in North America, Europe and Asia. The trial is currently ongoing.

In February 2009, laquinimod received Fast Track designation from the U.S. Food and Drug Administration (FDA).

Continue to read by clicking here


Thousands of Cyclists ride in Various NMSS Bike tours

See below for three recent NMSS Bike Tour challenges to raise much needed money

Cyclists raise about $1.85 million for MS
Salt Lake Tribune - United States
More than 3000 registered to ride Saturday and Sunday and raise funds to fight multiple sclerosis. This year's fundraising goal is $1.8 million. ...

Thousands of cyclists raise money for MS - Denver,CO,USA
WESTMINSTER - Governor Ritter joined cyclists on Saturday for the two day ride for Multiple Sclerosis. Cyclists hope to raise more than three million ...

Cyclists ready to roll on Bike-to-Bay event
Toledo Blade - Toledo,OH,USA
The annual tour is named after Reeves Grant Northrup of Toledo, who died in 1999 at age 64, nearly 30 years after he was diagnosed with multiple sclerosis. ...


MULTIPLE SCLEROSIS: Biogen reports 10th case of PML brain infection

Reuters via Yahoo Finance:

BOSTON (Reuters) – A 10th patient taking Biogen Idec Inc's Tysabri has developed a potentially deadly brain infection since the multiple sclerosis drug was reintroduced to the market in July 2006, sending the company's shares down nearly 7 percent.

The Cambridge, Massachusetts-based biotech company released the news on its website late on Friday.

Tysabri, which Biogen sells in conjunction with Irish drugmaker Elan Corp Plc, is considered critical to the future growth of both companies.

The drug was temporarily withdrawn from the market in 2005 after it was linked with a brain infection known as progressive multifocal leukoencephalopathy, or PML. It was brought back in 2006 with stricter safety warnings.

Sales of the drug have failed to live up to expectations. It generated $227 million in the first quarter, less than the $246 million analysts had expected.

Biogen has recently begun taking a more aggressively upbeat tone in marketing the drug, insisting physicians are becoming more comfortable with risk of PML. Even so, some analysts believe doctors may take patients off the drug for certain periods of time.

"We view increased adoption of drug holidays as a strong possibility," said analyst Eun Yang of Jefferies & Co, whose 2009 sales estimate of $1 billion for Tysabri remains unchanged.

Analysts at Deutsche Bank downgraded Biogen shares to "hold" from "buy," and said the company no longer warranted being one of the bank's 'top picks' in 2009.

Biogen shares were down 6.8 percent at $46.66 in morning Nasdaq trading.

(Reporting by Toni Clarke; Editing by Steve Orlofsky and Lisa Von Ahn)


Living with Progressive MS - the Movie

Information provided by Karen in Tamarac, Fl.

"A Certain Kind of Beauty"

By Ashley Neglia

For the past 11 years, Dan Aronie's body has been ravaged by a rare form of progressive relapsing multiple sclerosis that attacks the central nervous system and steadily damages the nerves. At 33, his condition has deteriorated to such an extent that he can no longer live on his own. His tremors are so severe that he cannot feed or dress himself, and his body is so weak that he no longer has the strength to sit up on his own. Today he is dependent on 24-hour care from his family and hired caretakers, who help him get out of bed, dress, eat and go to the bathroom.

After being diagnosed at 23, his mother, Nancy Slonim Aronie, asked Dan if he wanted to record the disease's progression. He agreed, and with the help of family friend, Gerry Storrow, Nancy began filming her son's steady decline. When Nancy showed her personal footage to filmmakers Liz Witham and Ken Wentworth, it struck a personal note and the decision to create a documentary about Aronie's life was made.

Click here to continue reading

Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You